Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity
Publication: Research - peer-review › Journal article – Annual report year: 2012
Standard
Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. / Harndahl, Mikkel Nors; Rasmussen, Michael; Roder, Gustav; Dalgaard Pedersen, Ida; Sørensen, Mikael; Nielsen, Morten; Buus, Søren.
In: European Journal of Immunology, Vol. 42, No. 6, 2012, p. 1405-1416.Publication: Research - peer-review › Journal article – Annual report year: 2012
Harvard
APA
CBE
MLA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity
A1 - Harndahl,Mikkel Nors
A1 - Rasmussen,Michael
A1 - Roder,Gustav
A1 - Dalgaard Pedersen,Ida
A1 - Sørensen,Mikael
A1 - Nielsen,Morten
A1 - Buus,Søren
AU - Harndahl,Mikkel Nors
AU - Rasmussen,Michael
AU - Roder,Gustav
AU - Dalgaard Pedersen,Ida
AU - Sørensen,Mikael
AU - Nielsen,Morten
AU - Buus,Søren
PB - Wiley - V C H Verlag GmbH & Co. KGaA
PY - 2012
Y1 - 2012
N2 - Efficient presentation of peptide‐MHC class I (pMHC‐I) complexes to immune T cells should benefit from a stable peptide‐MHC‐I interaction. However, it has been difficult to distinguish stability from other requirements for MHC‐I binding, for example, affinity. We have recently established a high‐throughput assay for pMHC‐I stability. Here, we have generated a large database containing stability measurements of pMHC‐I complexes, and re‐examined a previously reported unbiased analysis of the relative contributions of antigen processing and presentation in defining cytotoxic T lymphocyte (CTL) immunogenicity [Assarsson et al., J. Immunol. 2007. 178: 7890–7901]. Using an affinity‐balanced approach, we demonstrated that immunogenic peptides tend to be more stably bound to MHC‐I molecules compared with nonimmunogenic peptides. We also developed a bioinformatics method to predict pMHC‐I stability, which suggested that 30% of the nonimmunogenic binders hitherto classified as “holes in the T‐cell repertoire” can be explained as being unstably bound to MHC‐I. Finally, we suggest that nonoptimal anchor residues in position 2 of the peptide are particularly prone to cause unstable interactions with MHC‐I. We conclude that the availability of accurate predictors of pMHC‐I stability might be helpful in the elucidation of MHC‐I restricted antigen presentation, and might be instrumental in future search strategies for MHC‐I epitopes.
AB - Efficient presentation of peptide‐MHC class I (pMHC‐I) complexes to immune T cells should benefit from a stable peptide‐MHC‐I interaction. However, it has been difficult to distinguish stability from other requirements for MHC‐I binding, for example, affinity. We have recently established a high‐throughput assay for pMHC‐I stability. Here, we have generated a large database containing stability measurements of pMHC‐I complexes, and re‐examined a previously reported unbiased analysis of the relative contributions of antigen processing and presentation in defining cytotoxic T lymphocyte (CTL) immunogenicity [Assarsson et al., J. Immunol. 2007. 178: 7890–7901]. Using an affinity‐balanced approach, we demonstrated that immunogenic peptides tend to be more stably bound to MHC‐I molecules compared with nonimmunogenic peptides. We also developed a bioinformatics method to predict pMHC‐I stability, which suggested that 30% of the nonimmunogenic binders hitherto classified as “holes in the T‐cell repertoire” can be explained as being unstably bound to MHC‐I. Finally, we suggest that nonoptimal anchor residues in position 2 of the peptide are particularly prone to cause unstable interactions with MHC‐I. We conclude that the availability of accurate predictors of pMHC‐I stability might be helpful in the elucidation of MHC‐I restricted antigen presentation, and might be instrumental in future search strategies for MHC‐I epitopes.
U2 - 10.1002/eji.201141774
DO - 10.1002/eji.201141774
JO - European Journal of Immunology
JF - European Journal of Immunology
SN - 0014-2980
IS - 6
VL - 42
SP - 1405
EP - 1416
ER -